Arcellx, Inc. (NasdaqGM: ACLX)
Health Care · Biotechnology · US
$—
— today · — 1Y
Arcellx, Inc. (NasdaqGM: ACLX) operates in the Biotechnology industry within the Health Care sector.
trading between 60.36 and 115.13.
Tweenvest scores Arcellx, Inc. across four factors: quality 42/100, value 39/100. Its strongest factor is quality.
ACLX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- $22.29M
- P/E
- —
- EPS
- -4.07
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $115.13
- 52-week low
- $60.36
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 163
- Next earnings
- —
About Arcellx, Inc.
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of additional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.
- ISIN
- US03940C1009
- Founded
- 2014
- Listed since
- Feb 4, 2022
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| PhaseRx, Inc.OTCPK: PZRX.Q | $12.00 | $— | — |
| ContraFect CorporationOTCPK: CFRX.Q | $11.00 | $0.00 | — |
| Notable Labs, Ltd.OTCPK: NTBL.Q | $10.00 | $— | — |
| OncoSec Medical IncorporatedOTCPK: ONCS.Q | $6.00 | $0.00 | — |
| Calithera Biosciences, Inc.OTCPK: CALA | $5.00 | $0.00 | -99.00% |
| Biocept, Inc.OTCPK: BIOC.Q | $3.00 | $0.00 | -99.50% |
| Yield10 Bioscience, Inc.OTCPK: YTEN.Q | $1.00 | $— | — |
| LadRx CorporationOTCPK: LADX | $0.00 | $0.00 | -99.50% |
Figures last refreshed Oct 18, 2026.